SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 40,000
-100 (-0.25%)
Jun 16, 2026, 3:30 PM KST
SK bioscience Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, SK bioscience stock has a consensus rating of "Sell" and an average price target of ₩32,750. The average 1-year stock price forecast is 18.13% lower than the current stock price, while the lowest is ₩23,000 (-42.50%) and the highest is ₩46,000 (+15.00%).
Price Target: ₩32,750 (-18.13%)
Analyst Consensus: Sell
Analyst Ratings
The average analyst rating for SK bioscience stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 2 | 2 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Total | 6 | 6 | 6 | 5 | 5 | 4 |
Financial Forecast
Revenue This Year
724.19B
from 651.37B
Increased by 11.18%
Revenue Next Year
771.13B
from 724.19B
Increased by 6.48%
EPS This Year
-1.21K
from -733.00
EPS Next Year
-904.43
from -1.21K
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 760.0B | ||
| Avg | 724.2B | ||
| Low | 679.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.7% | ||
| Avg | 11.2% | ||
| Low | 4.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1,142.00 | ||
| Avg | -1,207.30 | ||
| Low | -1,272.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |